Research Site

Clayton, Victoria 3168

1 studies enrolling now · 11 studies all time

What they study most

Bone Metastases, Cancer, Chronic Lymphocytic Leukemia, Hematologic Malignancies, High-risk Diffuse Large B-cell Lymphoma, Hyperparathyroidism, Secondary, Hypophosphatasia (HPP), Multiple Myeloma, Multiple Myeloma Bone Lesions, Multiple Sclerosis, Oncology, Relapsed or Refractory Multiple Myeloma

Studies at this site

• Registry of Patients With Hypophosphatasia — Enrolling by invitation
• Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma — Completed
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS) — Completed
• Dimethyl Fumarate (DMF) Observational Study — Completed
• Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma — Completed
• Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) — Stopped early
• Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT) — Stopped early
• Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis — Completed
• Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis — Completed
• Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis — Completed
• Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) — Stopped early